Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Penicillins	O
/	O
niacin	O
Attending:	O
___	O
Chief	O
Complaint:	O
nausea,	O
___	O
metastases	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Lumbar	O
Puncture	O
x	O
2	O
PICC	O
placement	O
Bone	O
Marrow	O
Biopsy	O
History	O
of	O
Present	O
Illness:	O
Primary	O
Oncologist:	O
Dr	O
___	O
Care	O
___:	O
Dr	O
___	O
___	O
Regimen:	O
R	O
CHOP	O
Primary	O
Disease:	O
CD20-positive	O
B-cell	O
lymphoma	O
Chief	O
Complaint:	O
___	O
Metastases	O
HPI:	O
Ms.	O
___	O
is	O
a	O
___	O
woman	O
with	O
hx	O
of	O
high-grade	O
lambda-restricted	O
CD20-positive	O
B-cell	O
lymphoma	O
with	O
complex	O
karyotype	O
s/p	O
R-EPOCH	O
x	O
5,	O
Rituxan	O
x	O
1	O
presenting	O
for	O
transfer	O
from	O
___	O
with	O
___	O
metastases.	O
She	O
presented	O
initially	O
to	O
the	O
___	O
on	O
___	O
with	O
encephalopathy.	B-Delirium
CT	O
scan	O
showed	O
___	O
masses	O
and	O
she	O
is	O
being	O
admitted	O
for	O
further	O
workup	O
and	O
evaluation.	O
According	O
to	O
the	O
daughter	O
the	O
patient	O
was	O
very	O
confused	B-Delirium
on	O
___.	O
The	O
patient	O
denied	O
any	O
headache,	O
dizziness,	O
or	O
change	B-Visual_impairment
in	B-Visual_impairment
the	B-Visual_impairment
vision	B-Visual_impairment
but	O
complained	O
of	O
nausea	O
and	O
upset	O
stomach	O
x	O
1	O
wk.	O
CT	O
of	O
the	O
head	O
showed	O
a	O
right	O
frontal	O
lobe	O
and	O
left	O
basal	O
ganglion	O
perithalamic	O
masses	O
highly	O
concerning	O
for	O
malignancy	O
without	O
midline	O
shift.	O
Per	O
the	O
discharge	O
paperwork,	O
her	O
encephalopathy	B-Delirium
improved	O
with	O
IVF	O
only;	O
no	O
medications	O
aside	O
from	O
what	O
she	O
takes	O
at	O
home	O
were	O
given.	O
She	O
was	O
then	O
transferred	O
to	O
___	O
on	O
___	O
___	O
for	O
further	O
management.	O
.	O
On	O
arrival,	O
her	O
main	O
concern	O
is	O
her	O
T12	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
pain	O
which	O
is	O
chronic	O
for	O
___	O
years;	O
it	O
is	O
worse	O
but	O
has	O
no	O
no	O
other	O
change	O
in	O
characteristics.	O
She	O
also	O
states	O
that	O
she	O
had	O
rinorrhea	O
for	O
2	O
weeks	O
and	O
a	O
dry	O
cough	O
for	O
one	O
week.	O
Her	O
only	O
sick	O
contact	O
is	O
her	O
daughter	O
who	O
may	O
have	O
had	O
a	O
gastrointestinal	O
illness	O
last	O
week.	O
She	O
reports	O
having	O
a	O
possible	O
fever	O
1	O
week	O
ago	O
but	O
none	O
since.	O
.	O
REVIEW	O
OF	O
SYSTEMS:	O
(+)	O
Per	O
HPI;	O
constipation	B-Constipation
(-)	O
Denies	O
headache,	O
shortness	O
of	O
breath,	O
or	O
wheezing.	O
Denies	O
chest	O
pain,	O
chest	O
pressure,	O
or	O
weakness.	O
Denies	O
vomiting,	O
diarrhea,	O
abdominal	O
pain.	O
Denies	O
dysuria,	O
arthralgias	O
or	O
myalgias.	O
Denies	O
rashes	O
or	O
skin	O
changes.	O
All	O
other	O
ROS	O
negative	O
.	O
Past	O
Medical	O
History:	O
PAST	O
ONCOLOGIC	O
HISTORY:	O
-	O
High-grade	O
lambda-restricted	O
CD20-positive	O
B-cell	O
lymphoma	O
with	O
complex	O
karyotype	O
s/p	O
R-EPOCH	O
x	O
5,	O
Rituxan	O
x	O
1	O
-	O
MGUS	O
TREATMENT	O
HISTORY:	O
___	O
-	O
cycle	O
1	O
EPOCH	O
___	O
-	O
cycle	O
1	O
Rituxan	O
over	O
2	O
days	O
___	O
-	O
cycle	O
2	O
EPOCH	O
___	O
-	O
cycle	O
2	O
Rituxan	O
___	O
-	O
cycle	O
3	O
EPOCH	O
___	O
-	O
cycle	O
3	O
Rituxan	O
Restaging	O
CT	O
torso	O
on	O
___	O
-	O
spleen	O
decreased	O
to	O
normal	O
size,	O
incidental	O
finding	O
of	O
a	O
PE	O
->	O
started	O
on	O
anticoagulation	O
with	O
Lovenox	O
Restaging	O
bone	O
marrow	O
biopsy	O
on	O
___	O
-	O
no	O
evidence	O
of	O
involvement	O
by	O
lymphoma	O
___	O
-	O
cycle	O
4	O
EPOCH	O
___	O
-	O
cycle	O
4	O
Rituxan	O
___	O
-	O
cycle	O
5	O
EPOCH	O
___	O
-	O
cycle	O
5	O
Rituxan	O
___	O
-	O
cycle	O
6	O
Rituxan	O
PAST	O
MEDICAL/SURGICAL	O
HISTORY:	O
Gastroesophageal	O
reflux	O
Hyperlipidemia	O
Cholelithiasis	O
Osteoarthritis	O
Obstructive	O
sleep	O
apnea	O
Hearing	B-Hearing_impairment
loss	B-Hearing_impairment
with	O
R	O
cochlear	B-Hearing_impairment
implant	B-Hearing_impairment
History	O
of	O
T12	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
History	O
of	O
pericardial	O
effusions	O
in	O
___	O
Pulmonary	O
Embolism,	O
incidental,	O
noted	O
in	O
___	O
Social	O
History:	O
___	O
Family	O
History:	O
2	O
brothers	O
with	O
diabetes.	O
1	O
brother	O
had	O
liver	O
cancer	O
and	O
a	O
sister	O
had	O
lung	O
cancer.	O
Physical	O
Exam:	O
ADMISSION	O
Vitals:	O
T	O
97.9	O
bp	O
129/74	O
HR	O
62	O
RR	O
18	O
SaO2	O
98	O
RA	O
GEN:	O
NAD,	O
awake,	O
alert,	O
intermittantly	O
tearful	O
HEENT:	O
supple	O
neck,	O
dry	O
mucous	O
membranes,	O
no	O
oropharyngeal	O
lesions	O
PULM:	O
normal	O
effort,	O
CTAB	O
CV:	O
RRR,	O
no	O
r/m/g/heaves	O
ABD:	O
soft,	O
NT,	O
ND,	O
bowel	O
sounds	O
present	O
EXT:	O
normal	O
perfusion,	O
slight	O
edema	O
SKIN:	O
warm,	O
dry	O
NEURO:	O
AOx2	B-Unspecified_cognitive_impairment
but	O
logical	O
CN	O
II-XII	O
intact,	O
no	O
focal	O
sensory	O
or	O
motor	O
deficits	O
PSYCH:	O
calm,	O
cooperative	O
DISCHARGE	O
98.2	O
121/50	O
60	O
18	O
94%	O
RA	O
GEN:	O
NAD,	O
awake,	O
alert	O
HEENT:	O
supple	O
neck,	O
MMM,	O
no	O
oropharyngeal	O
lesions	O
PULM:	O
normal	O
effort,	O
Mild	O
right	O
basilar	O
crackles	O
CV:	O
RRR,	O
no	O
r/m/g/heaves	O
ABD:	O
soft,	O
NT,	O
ND,	O
bowel	O
sounds	O
present	O
EXT:	O
normal	O
perfusion,	O
slight	O
edema	O
of	O
L>R	O
UE	O
SKIN:	O
warm,	O
dry	O
NEURO:	O
CN	O
II-XII	O
intact.	O
grossly	O
nonfocal	O
PSYCH:	O
calm,	O
cooperative	O
Pertinent	O
Results:	O
ADMISSION	O
___	O
01:00AM	O
BLOOD	O
WBC-7.8	O
RBC-3.76*	O
Hgb-11.8*	O
Hct-33.9*	O
MCV-90	O
MCH-31.3	O
MCHC-34.8	O
RDW-13.3	O
Plt	O
___	O
___	O
01:00AM	O
BLOOD	O
Neuts-82.1*	O
Lymphs-14.1*	O
Monos-2.9	O
Eos-0.6	O
Baso-0.2	O
___	O
05:45AM	O
BLOOD	O
Hypochr-NORMAL	O
Anisocy-NORMAL	O
Poiklo-2+	O
Macrocy-NORMAL	O
Microcy-NORMAL	O
Polychr-NORMAL	O
Ovalocy-2+	O
Pencil-OCCASIONAL	O
___	O
01:00AM	O
BLOOD	O
___	O
PTT-28.0	O
___	O
___	O
01:00AM	O
BLOOD	O
Glucose-132*	O
UreaN-16	O
Creat-0.7	O
Na-141	O
K-4.3	O
Cl-109*	O
HCO3-22	O
AnGap-14	O
___	O
01:00AM	O
BLOOD	O
ALT-36	O
AST-22	O
LD(LDH)-172	O
AlkPhos-64	O
TotBili-0.3	O
___	O
01:00AM	O
BLOOD	O
Calcium-9.4	O
Phos-3.7	O
Mg-1.9	O
___	O
05:59AM	O
BLOOD	O
Albumin-3.7	O
Calcium-9.3	O
Phos-3.6	O
Mg-2.1	O
UricAcd-4.1	O
___	O
11:26AM	O
URINE	O
Color-Straw	O
Appear-Clear	O
Sp	O
___	O
___	O
11:26AM	O
URINE	O
Blood-NEG	O
Nitrite-NEG	O
Protein-NEG	O
Glucose-NEG	O
Ketone-NEG	O
Bilirub-NEG	O
Urobiln-NEG	O
pH-7.0	O
Leuks-SM	O
___	O
01:48PM	O
URINE	O
RBC-5*	O
WBC-1	O
Bacteri-FEW	O
Yeast-NONE	O
Epi-0	O
DISCHARGE	O
___	O
05:35AM	O
BLOOD	O
WBC-7.5	O
RBC-3.30*	O
Hgb-10.3*	O
Hct-30.8*	O
MCV-93	O
MCH-31.3	O
MCHC-33.6	O
RDW-14.0	O
Plt	O
___	O
___	O
05:35AM	O
BLOOD	O
Neuts-86.3*	O
Lymphs-12.1*	O
Monos-1.3*	O
Eos-0.4	O
Baso-0	O
___	O
05:35AM	O
BLOOD	O
Glucose-131*	O
UreaN-19	O
Creat-0.7	O
Na-143	O
K-3.8	O
Cl-104	O
HCO3-34*	O
AnGap-9	O
___	O
05:35AM	O
BLOOD	O
ALT-85*	O
AST-19	O
LD(LDH)-142	O
AlkPhos-43	O
TotBili-0.4	O
___	O
05:35AM	O
BLOOD	O
Albumin-3.1*	O
Calcium-8.7	O
Phos-4.2	O
Mg-2.3	O
___	O
06:27AM	O
BLOOD	O
b2micro-1.7	O
___	O
10:30PM	O
BLOOD	O
mthotrx-2.5	O
___	O
10:32PM	O
BLOOD	O
mthotrx-0.23	O
___	O
10:57PM	O
BLOOD	O
mthotrx-0.09	O
CSF:	O
___	O
02:29PM	O
CEREBROSPINAL	O
FLUID	O
(CSF)	O
WBC-12	O
RBC-9*	O
Polys-0	O
___	O
___	O
02:29PM	O
CEREBROSPINAL	O
FLUID	O
(CSF)	O
WBC-24	O
RBC-2*	O
Polys-1	O
___	O
___	O
09:20AM	O
CEREBROSPINAL	O
FLUID	O
(CSF)	O
WBC-4	O
RBC-4*	O
Polys-0	O
___	O
___	O
09:20AM	O
CEREBROSPINAL	O
FLUID	O
(CSF)	O
WBC-9	O
RBC-2*	O
Polys-1	O
___	O
___	O
02:29PM	O
CEREBROSPINAL	O
FLUID	O
(CSF)	O
TotProt-90*	O
Glucose-86	O
Toxo	O
negative	O
CSF	O
Culture	O
Negative	O
Urine	O
Culture	O
URINE	O
CULTURE	O
(Final	O
___:	O
ENTEROCOCCUS	O
SP..	O
>100,000	O
ORGANISMS/ML..	O
Levofloxacin	O
,	O
CIPROFLOXACIN	O
AND	O
LINEZOLID	O
Susceptibility	O
testing	O
requested	O
by	O
___.	O
___	O
ON	O
___.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
ENTEROCOCCUS	O
SP.	O
|	O
AMPICILLIN------------	O
<=2	O
S	O
CIPROFLOXACIN---------	O
=>8	O
R	O
LEVOFLOXACIN----------	O
=>8	O
R	O
LINEZOLID-------------	O
2	O
S	O
NITROFURANTOIN--------	O
<=16	O
S	O
TETRACYCLINE----------	O
=>16	O
R	O
VANCOMYCIN------------	O
1	O
S	O
C	O
Diff	O
Negative	O
Blood	O
Cx	O
Negative	O
IMAGING:	O
CTA	O
Chest,	O
CT	O
A/P	O
___:	O
1.	O
No	O
CT	O
evidence	O
for	O
recurrent	O
lymphadenopathy.	O
2.	O
Diminutive	O
bilateral	O
lower	O
lobe	O
subsegmental	O
arteries,	O
reflecting	O
chronic	O
incompletely-recannulized	O
vessels	O
from	O
previously-seen	O
pulmonary	O
emboli.	O
No	O
new	O
pulmonary	O
embolus.	O
3.	O
Interval	O
decrease	O
in	O
size	O
of	O
a	O
nonocclusive	O
right	O
common	O
iliac	O
vein	O
thrombus.	O
4.	O
Unchanged	O
goiter.	O
5.	O
Abnormal	O
pelvic	O
floor	O
descent.	O
6.	O
calcified	O
splenic	O
artery	O
aneurysms.	O
7.	O
Chronic	O
moderate	O
T12	O
wedge	O
compression	O
deformity.	O
CT	O
Head	O
with	O
contrast	O
___:	O
There	O
are	O
postsurgical	O
changes	O
which	O
appear	O
to	O
relate	O
to	O
right	O
cochlear	B-Hearing_impairment
implant.	B-Hearing_impairment
There	O
is	O
associated	O
artifact	O
which	O
obscures	O
some	O
portions	O
of	O
the	O
right	O
cerebral	O
hemisphere.	O
There	O
are	O
multiple	O
enhancing	O
masses	O
within	O
the	O
___	O
consistent	O
with	O
malignancy,	O
as	O
follows:	O
Mass	O
within	O
the	O
right	O
frontal	O
white	O
matter,	O
2.8	O
x	O
2.3	O
x	O
2.1	O
cm,	O
somewhat	O
irregularly	O
shaped,	O
with	O
associated	O
white	O
matter	O
edema.	O
Mass	O
within	O
the	O
right	O
occipital	O
lobe	O
apparently	O
abutting	O
the	O
occipital	O
horn	O
of	O
the	O
lateral	O
ventricle,	O
2.0	O
x	O
1.4	O
x	O
1.4	O
cm.	O
Mass	O
within	O
left	O
frontal	O
white	O
matter,	O
abutting	O
the	O
frontal	O
horn	O
of	O
the	O
lateral	O
ventricle,	O
1.7	O
x	O
1.3	O
x	O
1.3	O
cm,	O
with	O
associated	O
white	O
matter	O
edema.	O
Mass	O
in	O
the	O
right	O
basal	O
ganglia	O
region,	O
apparently	O
in	O
the	O
region	O
of	O
the	O
anterior	O
limb	O
of	O
the	O
internal	O
capsule,	O
somewhat	O
obscured	O
by	O
artifact,	O
1.2	O
x	O
1.1	O
x	O
0.9	O
cm.	O
There	O
is	O
an	O
adjacent	O
more	O
linear	O
area	O
of	O
enhancement	O
along	O
the	O
ventricle.	O
Mass	O
along	O
the	O
inferior	O
aspect	O
of	O
the	O
corpus	O
callosum	O
to	O
the	O
right	O
of	O
midline	O
abutting	O
the	O
medial	O
margin	O
of	O
the	O
right	O
lateral	O
ventricle,	O
1.3	O
x	O
1.1	O
x	O
0.9	O
cm.	O
Mass	O
along	O
the	O
inferior	O
aspect	O
of	O
the	O
corpus	O
callosum	O
to	O
the	O
left	O
of	O
midline	O
abutting	O
the	O
medial	O
margin	O
of	O
the	O
left	O
lateral	O
ventricle,	O
1.1	O
x	O
0.9	O
x	O
0.6	O
cm.	O
No	O
intracranial	B-Intracranial_haemorrhage
hemorrhage	B-Intracranial_haemorrhage
is	O
evident.	O
There	O
is	O
no	O
midline	O
shift.	O
There	O
is	O
no	O
hydrocephalus.	O
Basal	O
cisterns	O
are	O
patent.	O
Impression:	O
Multiple	O
enhancing	O
masses	O
within	O
the	O
___	O
consistent	O
with	O
malignancy.	O
LUE	O
___	O
___:	O
No	O
evidence	O
of	O
DVT	O
in	O
the	O
left	O
upper	O
extremity	O
veins.	O
PATHOLOGY	O
CSF	O
CYTOLOGY	O
___:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
IMMUNOTYPING	O
CSF	O
___:	O
RESULTS:	O
Three	O
color	O
gating	O
is	O
performed	O
(light	O
scatter	O
vs.	O
CD45)	O
to	O
optimize	O
lymphocyte	O
yield.	O
Due	O
to	O
paucicellular	O
nature	O
of	O
the	O
specimen,	O
a	O
limited	O
panel	O
is	O
performed	O
to	O
determine	O
B-cell	O
clonality.	O
B	O
cells	O
are	O
scant	O
in	O
number	O
precluding	O
evaluation	O
of	O
clonality.	O
T	O
cells	O
comprise	O
97%	O
of	O
lymphoid	O
gated	O
events.	O
INTERPRETATION	O
Non-diagnostic	O
study.	O
Clonality	O
could	O
not	O
be	O
assessed	O
in	O
this	O
case	O
due	O
to	O
insufficient	O
numbers	O
of	O
B	O
cells.	O
Cell	O
marker	O
analysis	O
was	O
attempted,	O
but	O
was	O
non-diagnostic	O
in	O
this	O
case	O
due	O
to	O
insufficient	O
numbers	O
of	O
cells.	O
If	O
clinically	O
indicated,	O
we	O
recommend	O
a	O
repeat	O
specimen	O
be	O
submitted	O
to	O
the	O
flow	O
cytometry	O
laboratory.	O
BONE	O
MARROW	O
___	O
CELLULAR	O
MARROW	O
FOR	O
AGE	O
WITH	O
MILD	O
TRILINEAGE	O
DYSPOIESIS	O
AND	O
NO	O
MORPHOLOGIC	O
EVIDENCE	O
OF	O
INVOLVEMENT	O
BY	O
LARGE	O
CEL	O
LYMPHOMA.	O
Note:	O
The	O
possibility	O
of	O
a	O
myelodysplastic	O
syndrome	O
needs	O
to	O
be	O
entertained	O
in	O
this	O
patient	O
with	O
history	O
of	O
therapy	O
with	O
R-EPOCH.	O
Please	O
correlate	O
with	O
clinical	O
and	O
cytogenetic	O
findings.	O
MICROSCOPIC	O
DESCRIPTION	O
peripheral	O
blood	O
smear:	O
The	O
smear	O
is	O
adequate	O
for	O
evaluation.	O
Erythrocytes	O
are	O
normochromic,	O
and	O
normocytic	O
and	O
have	O
marked	O
anisopoikilocytosis	O
including	O
elliptocytes	O
and	O
spherocytes,	O
echinocytes,	O
polychromatophils,	O
and	O
nucleated	O
RBC	O
are	O
seen.	O
The	O
white	O
blood	O
cell	O
count	O
is	O
normal	O
with	O
left	O
shifted	O
maturation.	O
Neutrophils	O
exhibit	O
toxic	O
vacuolization,	O
hypogranulation	O
and	O
rarely,	O
hypolobation.	O
The	O
platelet	O
count	O
appears	O
normal.	O
Occasional	O
large	O
and	O
giant	O
platelets	O
are	O
seen.	O
A	O
200	O
cell	O
differential	O
shows:	O
78%	O
neutrophils,	O
1%	O
bands,	O
17%	O
lymphocytes,	O
4%	O
monocytes.	O
aspirate	O
smear:	O
The	O
aspirate	O
material	O
is	O
adequate	O
for	O
evaluation	O
and	O
consists	O
of	O
multiple	O
cellular	O
spicules.	O
The	O
M:E	O
ratio	O
is	O
1.1:	O
1.	O
Erythroid	O
precursors	O
are	O
relatively	O
increased	O
in	O
number	O
and	O
have	O
megaloblastoid	O
and	O
dyspoietic	O
maturation,	O
including	O
cells	O
with	O
irregular	O
satellite	O
nuclei,	O
and	O
nuclear	O
cytoplasmic	O
dyssynchrony.	O
Myeloid	O
precursors	O
are	O
relatively	O
decreased	O
in	O
number	O
and	O
show	O
mildly	O
dyspoietic	O
maturation,	O
including	O
rare	O
hypolobated	O
cells.	O
Megakaryocytes	O
are	O
normal	O
in	O
number.	O
Abnormal	O
forms	O
are	O
seen	O
including	O
rare	O
hypolobated	O
cells.	O
Foci	O
of	O
increased	O
stripped	O
nuclei	O
are	O
present.	O
Scattered	O
histiocytes	O
with	O
ingested	O
cellular	O
debris	O
are	O
also	O
seen.	O
A	O
500	O
cell	O
differential	O
shows:	O
1%	O
blasts,	O
3%	O
promyelocytes,	O
11%	O
myelocytes,	O
4%	O
metamyelocytes,	O
33%	O
bands/neutrophils,	O
38%	O
erythroids,	O
9%	O
lymphocytes,	O
1%	O
plasma	O
cells.	O
clot	O
section	O
and	O
biopsy	O
slides:	O
The	O
core	O
biopsy	O
material	O
is	O
adequate	O
for	O
evaluation.	O
It	O
consists	O
of	O
a	O
fragmented,	O
in	O
total	O
1	O
cm	O
core	O
biopsy	O
of	O
trabecular	O
marrow	O
with	O
a	O
variable	O
cellularity	O
of	O
___.	O
The	O
M:E	O
ratio	O
estimate	O
is	O
normal.	O
Erythroid	O
precursors	O
are	O
normal	O
in	O
number,	O
and	O
have	O
overall	O
normoblastic	O
maturation.	O
Myeloid	O
precursors	O
are	O
normal	O
in	O
number,	O
with	O
normal	O
maturation.	O
Megakaryocytes	O
are	O
normal	O
in	O
number	O
with	O
focal	O
loose	O
clustering.	O
CSF	O
IMMUNOPHENOTYPING	O
___:	O
RESULTS:	O
Three	O
color	O
gating	O
is	O
performed	O
(light	O
scatter	O
vs.	O
CD45)	O
to	O
optimize	O
lymphocyte	O
yield.	O
Due	O
to	O
paucicellular	O
nature	O
of	O
the	O
specimen,	O
a	O
limited	O
panel	O
is	O
performed	O
to	O
determine	O
B-cell	O
clonality.	O
B	O
cells	O
are	O
scant	O
in	O
number	O
precluding	O
evaluation	O
of	O
clonality.	O
INTERPRETATION	O
Non-diagnostic	O
study.	O
Clonality	O
could	O
not	O
be	O
assessed	O
in	O
this	O
case	O
due	O
to	O
insufficient	O
number	O
cells.	O
Cell	O
marker	O
analysis	O
was	O
attempted	O
but	O
was	O
non-diagnostic	O
in	O
this	O
case	O
due	O
to	O
insufficient	O
numbers	O
of	O
cells.	O
If	O
clinically	O
indicated,	O
we	O
recommend	O
a	O
repeat	O
specimen	O
be	O
submitted	O
to	O
the	O
flow	O
cytometry	O
laboratory.	O
BM	O
IMMUNOPHENOTYPING	O
___:	O
FLOW	O
CYTOMETRY	O
IMMUNOPHENOTYPING	O
The	O
following	O
tests	O
(antibodies)	O
were	O
performed:	O
___,	O
FMC-7,	O
Kappa,	O
Lambda,	O
and	O
CD	O
antigens	O
3,5,10,19,20,23	O
and	O
45.	O
CD45	O
bright,	O
low	O
side	O
scatter	O
lymphocytes	O
represent	O
~7%	O
of	O
total	O
events.	O
B	O
cells	O
comprise	O
<1%	O
of	O
lymphoid-gated	O
events.	O
T	O
cells	O
comprise	O
94%	O
of	O
lymphoid	O
gated	O
events.	O
INTERPRETATION	O
Nonspecific	O
T-cell	O
dominant	O
lymphoid	O
profile;	O
diagnostic	O
immunophenotypic	O
features	O
of	O
involvement	O
by	O
a	O
non-Hodgkin	O
B-cell	O
lymphoma	O
are	O
not	O
seen	O
in	O
specimen.	O
Correlation	O
with	O
clinical	O
findings	O
and	O
morphology	O
(see	O
___	O
is	O
recommended.	O
Flow	O
cytometry	O
immunophenotyping	O
may	O
not	O
detect	O
all	O
lymphomas	O
due	O
to	O
topography,	O
sampling	O
or	O
artifacts	O
of	O
sample	O
preparation.	O
BM	O
CYTOLOLGY	O
___:	O
ATYPICAL.	O
Large	O
atypical	O
lymphocytes.	O
Further	O
classification	O
is	O
not	O
possible.	O
Brief	O
Hospital	O
Course:	O
Ms.	O
___	O
is	O
a	O
___	O
woman	O
status	O
post	O
treatment	O
for	O
a	O
B-cell	O
lymphoma	O
with	O
new	O
___	O
lesions	O
concerning	O
for	O
CNS	O
recurrence.	O
ACUTE	O
#	O
CD20-positive	O
B-cell	O
lymphoma	O
now	O
with	O
CNS	O
Recurrence:	O
s/p	O
five	O
cycles	O
of	O
R-EPOCH	O
and	O
scheduled	O
to	O
receive	O
Rituxan	O
every	O
three	O
months	O
as	O
maintenance	O
therapy.	O
Pt	O
initially	O
presented	O
to	O
___	O
with	O
encephalopathy	B-Delirium
at	O
which	O
time	O
periventricular	O
___	O
lesions	O
were	O
identified	O
with	O
cerebral	O
edema.	O
There	O
was	O
no	O
focal	O
e/o	O
neurological	O
compromise.	O
She	O
was	O
transferred	O
here	O
for	O
further	O
management	O
where	O
she	O
was	O
started	O
on	O
dexamethasone	O
q6hrs.	O
Bone	O
marrow	O
showed	O
no	O
e/o	O
involvement	O
and	O
CT	O
of	O
the	O
torso	O
showed	O
no	O
lymphadenopathy	O
or	O
splenomegaly.	O
LP	O
was	O
performed	O
and	O
results	O
were	O
somewhat	O
equivical,	O
demonstrating	O
atypical	O
lymphocytes.	O
PCR	O
for	O
a	O
B-cell	O
receptor	O
rearrangement	O
was	O
also	O
somewhat	O
equivocal.	O
Clonality	O
could	O
not	O
be	O
accessed	O
by	O
immunophenotyping.	O
Gram	O
stain	O
and	O
culture	O
were	O
negative.	O
Toxo	O
was	O
negative.	O
In	O
discussion	O
with	O
family,	O
it	O
was	O
felt	O
that	O
the	O
likelihood	O
of	O
this	O
being	O
CNS	O
recurrence	O
of	O
lymphoma	O
was	O
high.	O
Empiric	O
radiation	O
therapy	O
and	O
high	O
dose	O
methotrexate	O
were	O
discussed.	O
___	O
biopsy	O
was	O
deferred	O
given	O
high	O
likelihood	O
to	O
represent	O
lymphoma.	O
Pt	O
was	O
started	O
on	O
high	O
dose	O
methotrexate	O
once	O
sufficient	O
alkalinization	O
of	O
urine	O
was	O
achieved.	O
Renal	O
function	O
was	O
closely	O
monitored.	O
Levels	O
were	O
monitored	O
and	O
she	O
was	O
discharged	O
once	O
MTX	O
levels	O
were	O
<0.1.	O
Followup	O
was	O
arranged	O
with	O
Dr.	O
___	O
further	O
course	O
of	O
MTX	O
and	O
rituxan	O
will	O
be	O
discussed	O
at	O
that	O
time.	O
Prior	O
to	O
discharge,	O
dexamethasone	O
was	O
weened	O
to	O
once	O
daily	O
dosing.	O
Discharged	O
on	O
bactrim	O
and	O
acyclovir	O
ppx.	O
#	O
Bacteuria:	O
In	O
the	O
setting	O
of	O
mild	O
confusion	B-Delirium
and	O
pending	O
immunosuppression,	O
pt	O
was	O
initially	O
started	O
on	O
cipro	O
on	O
admission.	O
Culture	O
however	O
showed	O
enterococcus	O
only	O
sensitive	O
to	O
ampicillin,	O
macrobid,	O
and	O
vancomycin.	O
Pt	O
was	O
transitioned	O
to	O
vancomycin	O
and	O
then	O
macrobid	O
for	O
a	O
total	O
of	O
___iarrhea:	O
concern	O
for	O
C	O
diff	O
initially,	O
though	O
testing	O
was	O
negative.	O
Resolved	O
with	O
discontinuation	O
of	O
abx.	O
CHRONIC	O
#	O
Pulmonary	O
embolus:	O
Found	O
incidentally	O
on	O
___.	O
Started	O
on	O
lovenox	O
which	O
discontinued	O
on	O
___.	O
Her	O
CT	O
at	O
that	O
time	O
showed	O
chronic	O
PE	O
which	O
was	O
not	O
completely	O
resolved.	O
Full-dose	O
anticoagulation	O
was	O
held	O
during	O
this	O
admission.	O
#	O
GERD:	O
Pt	O
was	O
continued	O
on	O
PPI	O
TRANSITIONAL	O
#	O
maintenance	O
rituxan	O
#	O
continue	O
discussions	O
for	O
repeat	O
MTX	O
dose	O
if	O
tolerating	O
well	O
#	O
determine	O
appropriate	O
steroid	O
course	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q8H	O
2.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
3.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
4.	O
Sulfameth/Trimethoprim	O
SS	O
1	O
TAB	O
PO	O
DAILY	O
5.	O
TraMADOL	O
(Ultram)	O
50	O
mg	O
PO	O
Q6H:PRN	O
pain	O
6.	O
Calcium	O
Carbonate	O
500	O
mg	O
PO	O
DAILY	O
7.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
8.	O
Multivitamins	O
W/minerals	O
1	O
TAB	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q8H	O
2.	O
Calcium	O
Carbonate	O
500	O
mg	O
PO	O
DAILY	O
3.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
4.	O
Multivitamins	O
W/minerals	O
1	O
TAB	O
PO	O
DAILY	O
5.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
6.	O
Sulfameth/Trimethoprim	O
SS	O
1	O
TAB	O
PO	O
DAILY	O
7.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
8.	O
Dexamethasone	O
4	O
mg	O
PO	O
DAILY	O
9.	O
TraMADOL	O
(Ultram)	O
50	O
mg	O
PO	O
Q6H:PRN	O
pain	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
CNS	O
Lymphoma	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Confused	B-Delirium
-	O
sometimes.	O
Level	O
of	O
Consciousness:	O
Lethargic	O
but	O
arousable.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	B-Mobile_with_assistance
requires	B-Mobile_with_assistance
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Dear	O
Ms	O
___,	O
It	O
was	O
a	O
pleasure	O
caring	O
for	O
you	O
during	O
your	O
recent	O
admission	O
to	O
___.	O
You	O
were	O
admitted	O
with	O
lesions	O
in	O
your	O
___	O
concerning	O
for	O
recurrence	O
of	O
your	O
lymphoma.	O
We	O
treated	O
you	O
with	O
steroids	O
and	O
high	O
dose	O
methotrexate.	O
You	O
will	O
need	O
to	O
have	O
a	O
follow	O
up	O
appointment	O
with	O
Dr.	O
___	O
this	O
week	O
to	O
monitor	O
your	O
progress.	O
Followup	O
Instructions:	O
___	O

